SCHEMBL20867520

SCHEMBL20867520

Brc1ccccc1-n1c2ccccc2c2ccsc21

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ PDE7A Q13946 4/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ HCAR1 Q9BXC0 1/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ GPR3 P46089 1/20 0.31
▸ FABP3 P05413 1/20 0.30
▸ FABP2 P12104 1/20 0.30
▸ FABP4 P15090 1/20 0.30
▸ FABP5 Q01469 1/20 0.30
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21064592 0.85 HTR6 (0.33) GSK3AGSK3BNPC1RAB9AHCAR1
SCHEMBL21064562 0.85 ACHE (0.36) KDM4EATML3MBTL1
SCHEMBL17932989 0.81 GSK3A (0.41) GSK3AGSK3BKDM4EATML3MBTL1
SCHEMBL782631 0.80 ALDH1A1 (0.50) GSK3AGSK3BKDM4EATML3MBTL1
SCHEMBL29521714 0.80 ALDH1A1 (0.50) GSK3AGSK3BKDM4EATML3MBTL1
SCHEMBL25277587 0.78 KDM4E (0.42) GSK3AGSK3BKDM4EATML3MBTL1
SCHEMBL22924443 0.76 L3MBTL1 (0.61) GSK3AGSK3BKDM4EATML3MBTL1
SCHEMBL12443243 0.74 KDM4E (0.44) KDM4EATML3MBTL1GPR3FABP3
SCHEMBL24442021 0.72 KDM4E (0.43) KDM4EATML3MBTL1ALDH1A1GPR3
SCHEMBL12181252 0.72 ELANE (0.41) ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10400002-B2 Iridium complex and organic electroluminescence device using the same UDC IRELAND LIMITED (IE) 2019-09-03 — — US disclosed
US-10312455-B2 Delayed fluorescence material for organic electroluminescence device LUMINESCENCE TECHNOLOGY CORP. (TW) 2019-06-04 — — US disclosed
US-20190100543-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2019-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190100543-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LAGE3, OXA1L, OPA1 GSK3A 2718/4885GSK3B 2909/4885KDM4E 2981/4885
US-10312455-B2 Delayed fluorescence material for organic electroluminescence device SOD1, GPX1, LEF1 GSK3A 3897/4885GSK3B 3918/4885KDM4E 3381/4885
US-10400002-B2 Iridium complex and organic electroluminescence device using the same IMPA1, OXA1L, OPA1 GSK3A 3185/4885GSK3B 3439/4885KDM4E 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback